4K18
Structure of PIM-1 kinase bound to 5-(4-cyanobenzyl)-N-(4-fluorophenyl)-7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide
4K18 の概要
| エントリーDOI | 10.2210/pdb4k18/pdb |
| 関連するPDBエントリー | 4K0Y 4K1B |
| 分子名称 | Serine/threonine-protein kinase pim-1, PHOSPHATE ION, 5-(4-cyanobenzyl)-N-(4-fluorophenyl)-7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide, ... (4 entities in total) |
| 機能のキーワード | pim-1, kinase domain, ser/thr kinase, atp-competitive, structure-based drug design, phosphorylation, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Isoform 2: Cytoplasm. Isoform 1: Cell membrane: P11309 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 32416.56 |
| 構造登録者 | |
| 主引用文献 | Wang, X.,Magnuson, S.,Pastor, R.,Fan, E.,Hu, H.,Tsui, V.,Deng, W.,Murray, J.,Steffek, M.,Wallweber, H.,Moffat, J.,Drummond, J.,Chan, G.,Harstad, E.,Ebens, A.J. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. Bioorg.Med.Chem.Lett., 23:3149-3153, 2013 Cited by PubMed Abstract: Pim kinases are promising targets for the development of cancer therapeutics. Among the three Pim isoforms, Pim-2 is particularly important in multiple myeloma, yet is the most difficult to inhibit due to its high affinity for ATP. We identified compound 1 via high throughput screening. Using property-based drug design and co-crystal structures with Pim-1 kinase to guide analog design, we were able to improve potency against all three Pim isoforms including a significant 10,000-fold gain against Pim-2. Compound 17 is a novel lead with low picomolar potency on all three Pim kinase isoforms. PubMed: 23623490DOI: 10.1016/j.bmcl.2013.04.020 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.051 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






